Hepatitis B Virus Reactivation Potentiated by Biologics

Eiichi Ogawa, Mike T. Wei, Mindie H. Nguyen

Research output: Contribution to journalReview articlepeer-review

2 Citations (Scopus)

Abstract

Hepatitis B virus (HBV) reactivation can be a serious complication for patients with chronic or resolved HBV infection when treated with biologics. For HBsAg-positive patients receiving biologics, the risk of HBV reactivation is moderate to high. HBsAg-negative/anti-HBc positive patients are at lower risk of HBV reactivation than HBsAg-positive patients. However, patients taking anti-CD20 agents, such as rituximab, have high risk of HBV reactivation (>10%), so antiviral prophylactic therapies are required. This review provides the different classes of biologics associated with HBV reactivation, stratifies the various reactivation risk levels by HBV status and biologic agent, and discusses management strategies.

Original languageEnglish
Pages (from-to)341-358
Number of pages18
JournalInfectious Disease Clinics of North America
Volume34
Issue number2
DOIs
Publication statusPublished - Jun 2020

All Science Journal Classification (ASJC) codes

  • Microbiology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Hepatitis B Virus Reactivation Potentiated by Biologics'. Together they form a unique fingerprint.

Cite this